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ABBREVIATIONS 
 
DH: Dentin Hypersensitivity 
 
AB: Air blast 
 
PS: Probe scratching 
 
VAS: Visual Analog Scale 
 
MSC: MS Coat One F 
 
NAN: Nanoseal 
 
TMD: Teeth Mate Desensitizer 
 
GLU: Gluma Desensitizer PowerGel 
 
HEMA: 2-hydroxyethylmethacrylate 
 
HA: Hydroxyapatite 
 
CaF2: Calcium Fluoride 
 
Ca3PO4: Calcium Phosphate 
 
CPD-100: Calcium Phosphate Dihydrate 
 
PRE: Preoperative 
 
POST: Postoperative 
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ABSTRACT 
Objective: To investigate the effects of four dentin desensitizers on pain reduction in 
hypersensitive cervical dentin lesions. Material and methods: The trial was designed as 
randomized, controlled, four-arm, single-masked study. Fifty subjects with at least one 
hypersensitive lesion in each of the four quadrants were allocated. The requested pre-operative 
pain, determined as response to 2 seconds air-blast (AB) and probe scratching (PS), was ≥ 5 on a 
VAS scale, 0=no through 10=worst pain. Randomly each subject received each of the four 
treatments: MS Coat One F (MSC, Sun Medical, Japan), Nanoseal (NAN, Nishin, Japan), 
Teethmate Desensitizer (TMD, Kuraray Noritake, Japan) and Gluma Desensitizer PowerGel 
(GLU, HeraeusKulzer, Germany). The investigator assessed blindly the pain response using the 
two stimuli and recorded the patients’ VAS scores before and immediately after application, after 
1week, and after 1, 3 and 6 months. Statistical data treatment: ANOVA and post-hoc testing 
(p≤0.05). Results: Forty-nine subjects completed the trial. Preoperative dentin hypersensitivity 
(DH) for the groups was not significantly different. All desensitizers reduced DH significantly 
throughout the 6-months observation. ANOVA revealed significant differences among VAS 
scores, obtained with the desensitizing agents (p<0.001). Ranking by post-hoc testing was: 
MSC>NAN>TMD>GLU (p<0.05). Upon PS NAN and TMD showed slight but significant regain 
of sensitivity after 6 months. For GLU PS scores immediately after application and after 6 months 
were not significantly different, whereas recalls after 1w, 1m and 3 m revealed significantly lower 
scores. Conclusion: The calcium phosphate based TMD and GLU proved highly effective in 
reducing sensitivity.  
	   3	  
INTRODUCTION 
Dentin hypersensitivity (DH) is defined as a short, sharp pain arising from exposed 
dentin in response to stimuli typically thermal, evaporative, tactile, osmotic or 
chemical and which cannot be ascribed to any other form of dental defect or 
pathology[1]. DH may occur when dentin is exposed to the oral cavity and when 
dentinal tubules are patent both at the pulpal and the oral surface [2]. Among the 
several theories put forward to explain how pain is transferred from the exposed 
dentin surface to the pulp the most widely accepted one is Brännström’s 
hydrodynamic theory [3,4]. According to this theory sensitivity of dentin is the result 
of stimulus-induced fluid flow in the dentinal tubules and concomitant activation of 
sensory nerves in the pulp/dentin border area[5]. On this background a reasonable 
therapy of DH should hamper or exclude fluid flow by tubular obstruction. For this 
purpose a plethora of agents and products is available on the market to modify the 
dentin surface or tubules by chemical, mechanical and physical means, such as protein 
precipitation, plugging of tubular entrances by crystal/salt precipitation, laser 
treatment and resin sealing [6,7]. 
 Literature reports on prevalence of DH show very large variations ranging from 3 
to 98% [8]. This heterogeneity is mainly explained by the selection criteria used for 
different study samples and especially by the selected diagnostic approaches [9]. DH 
is always a diagnosis of exclusion. Upon screening dentists must exclude by 
differential diagnoses clinical symptoms similar to cervical DH, such as cracked tooth 
syndrome, dental caries, pulpitis, to mention only a few [10,11]. 
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 In spite of the numerous agents and regimens suggested for in-office pain relief of 
DH there is no consensus on the efficacy of different therapeutic approaches [12]. 
Although in vitro assessments of the hydraulic conductance of dentin are frequently 
reported in the dental literature as a measure to quantify fluid flow inside dentinal 
tubules following different treatment modalities, such data may at the best be 
considered rough screening tools of potential clinical usefulness [13-15]. Thus, the 
ultimate proof of clinical effectiveness remains randomized controlled clinical testing. 
 For the present investigation four treatment modalities were selected and 
compared: sealing of dentin with an oxalate-containing pre-polymerized resin 
suspension, precipitation of calcium- and silicate phosphate from silicate glass mixed 
with phosphoric acid, hydroxyapatite precipitation from a calcium phosphate 
desensitizing agent, and dentinal liquid protein precipitation after topical application 
of a glutaraldehyde containing desensitizer.  
 Aim of this randomized, controlled, four-arm, single-blind trial was to investigate 
the effect of four different treatment approaches on patients’ perception of 
stimulus-provoked pain of hypersensitive cervical dentin over a six-months period. 
The null hypothesis tested was that the different topical treatments would significantly 
reduce DH throughout the six-months assessment time. 
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MATERIALS AND METHODS 
The “Guidelines for the design and conduct of clinical trials on dentine 
hypersensitivity” were adopted and followed during planning and execution of the 
study [12]. Approval for this clinical investigation was obtained from the ethics 
committee of the local University Review Board (VokkaligaraSangha Dental College 
and Hospital, Bangalore, India. Approval: VSDC/EC-16, 11/07/2013). The request to 
include a placebo or a no-treatment option was not approved by the ethical board. The 
study was conducted in agreement with the principles of the Declaration of Helsinki 
(World Medical Association Declaration of Helsinki, 2008). 
 Patients for this study were recruited from the Department of Conservative 
Dentistry and Endodontics, VokkaligaraSangha Dental College and Hospital, 
Bangalore, India. Main inclusion criterion was presence of at least one sensitive tooth 
in each of the four quadrants with a VAS (Visual Analogue Scale) score >5 cm on 
buccal cervical dentin. Seventy-two patients self-reporting tooth sensitivity were 
screened for participation in this trial. Exclusion criteria were systemic diseases, 
pulpitis, carious lesions, defective restorations, cracked enamel, active periodontal 
disease, medication with analgesic drugs, pregnant or lactating women and 
professional desensitizing treatment received during the preceding three months. Fifty 
patients were allocated to the study after obtaining written informed consent. For each 
patient the kind of treatment of the selected tooth in each quadrant was determined 
using a randomization table of the four treatment modalities. The list was produced on 
Research Randomizer Calculator (www.socialpsychology.org/randomizer.htm). If 
	   6	  
patients had two or more sensitive teeth in the same quadrant the tooth with the 
highest VAS score was selected, whereas the other teeth remained untreated at this 
time. According the study protocol all patients received oral hygiene instructions and 
a professional dental prophylaxis. 
 Table I shows the patients demographics and Table II gives the numbers of teeth 
by location and assigned treatment.One week prior to the treatment the investigator 
assessed dentin hypersensitivity using a cold air stimulus (two-second air blast from a 
dental syringe directed perpendicular to the lesion surface at 1 cm distance). 
Neighboring teeth were shielded with the gloved fingers of the investigator. 
Immediately after stimulation patients were asked to point on a VAS scale (no pain = 
0 and worst pain = 10 cm) to the nearest full centimeter number to describe their pain 
perception. Five minutes later, the investigator applied a tactile stimulus, running a 
dental explorer across the cervical area of the assigned teeth in horizontal and vertical 
direction at a relatively mild force, and the patients were asked again to give their 
VAS pain score.  
 The desensitizing agents, shown in Table III together with their composition and 
mode of application were used. Gluma Desensitizer PowerGel was used as positive 
control, since this desensitizer proved highly effective in a previous clinical study 
performed at this institution [17]. 
 Upon start of the trial the investigator determined the VAS scores as baseline 
(PRE) again as described above. Two calibrated operators performed the treatments 
according to instructions and the randomization table. Within 10 minutes after the last 
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treatment the investigator assessed sensitivity as immediate response (POST). Patients 
were recalled after 1 week, 1, 3 and 6 months for sensitivity screening. At each recall 
the investigator used blank sheets with patients numbers only to avoid bias relative to 
previous assessments. 
 
Statistical analysis 
The treated teeth were the experimental unit for the statistical analyses. Since the data were 
normally distributed statistical treatment was performed by parametric univariate ANOVA and 
Tukey’s post hoc test with a significance level set at p ≤ 0.05 (IBM SPSS Statistics, Version 21.0 
for Mac, Chicago, IL, USA). 
 
 
RESULTS 
From the 50 patients enrolled 49 completed the 6-month trial. One subject dropped 
out after the 1-month recall assessment due to moving to another city. No significant 
differences were detected regarding the pretreatment mean VAS scores for AB and PS, 
respectively. The box-and-whisker plots in Figures 1 and 2 illustrate the medians, the 
interquartile distances and extreme VAS scores for the 4 desensitizing products 
evaluated by testing stages and kind of stimulus, respectively. Figures 3 and 4 display 
the mean VAS scores registered after AB and PS stimulation at all time points. The 
error bars denote the 95% intervals of confidence.PS scores were slightly higher than 
AB scores. For all materials the BL scores were significantly higher than at any of the 
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following stages. All desensitizers reduced DH significantly throughout the 6-months 
observation. ANOVA revealed significant differences among VAS scores for the 
desensitizing agents both after AB and PS stimulation (p<0.001). Product ranking by 
post-hoc testing was: MSC>NAN>TMD>GLU (p<0.05). Upon AB stimulation 
sensitivity scores at time points POST through 6m were not significantly different for 
each desensitizing product tested.  
 
 
DISCUSSION 
The present clinical trial has proven that the four desensitizing agents tested all 
reduced sensitivity of cervical hypersensitivity lesions significantly, albeit to different 
levels. Thus, the null hypothesis tested that the different topical treatments would 
significantly reduce DH throughout the six-months assessment time has to be 
accepted. 
The most important factor in the etiology of dentin hypersensitivity is exposed dentin 
as a result of gingival recession associated with exposure of root surfaces and/or as a 
result of loss of enamel associated with tooth wear or trauma; followed by opening of 
the dentinal tubules (ie, 
loss of cementum or removal of any smear layer). In the present study most of the 
patients test sites reported sensitivity due to gingival recession. 
 In agreement with previous reports that females suffer from slightly higher 
incidence of dentin hypersensitivity, in the present study twice as many females as 
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men were identified for inclusion and the highest prevalence was in the 31-40 years 
group [8,9,18]. As reported previously most frequently hypersensitive teeth were 
premolars [18]. 
 According to the study protocol instead of placebo or a no-treatment option that 
was not approved by the ethical board, GLU was included as positive control to assess 
equivalence or superiority of the alternative products investigated [16]. 
 For pain evaluation both evaporative and tactile stimuli were applied 
(response-based assessment) and pain response was measured on a VAS scale. This 
rating scale is easily comprehensible and offers in addition the advantage of 
parametric statistical result evaluation [16]. 
 From the desensitizers tested MS Coat One F (MSC) showed the least reduction 
in sensitivity, approximately 1.5 VAS sores less than at baseline. MSC contains oxalic 
acid and a fluoride containing acid polymer. According to the manufacturer calcium 
oxalate is precipitated upon application to dentin and the acid polymer is claimed to 
provide a surface sealing film. In a clinical placebo-controlled study with the 
predecessor product MS Coat (US brand Pain-Free) no difference in pain reduction 
was found between MS Coat and a placebo formulation throughout three-months 
evaluation [19].Similarly, in a recently published systematic review of clinical trials 
of hypersensitivity oxalates were not found to be different from placebo, apart from 3% 
monohydrogen-monopotassium oxalate [20]. 
 NanoSeal (NAN) is a desensitizing compound recently introduced to the Japanese 
market. Regarding the composition this product seems to be a spin-off from silicate 
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cement. It is hypothesized that upon application of the acidic mix to the dentin surface 
CaF2, Ca3PO4 and phosphosilicate are precipitated into dentinal tubule entrances and 
on intertubular dentin. Immediately after application and throughout the entire 
assessment time VAS rating was reduced by almost 3 scores. The slight regain in 
sensitivity recorded at the six-months recall might indicate that the precipitate is 
gradually removed by mechanical action and/or erosion in dietary acids. 
 Teethmate Desensitizer (TMD) is a calcium-phosphate-based material. During 
more than two decades there has been considerable interest to develop 
calcium-phosphate compounds for treatment of dentin hypersensitivity [21-25]. 
Calcium-phosphate compounds are transferred to hydroxyapatite (HA), the main 
mineral phase in teeth. This means, that such products can be characterized as true 
biocompatible and biomimetic materials [24]. TMD is the first marketed 
calcium-phosphate containing desensitizer of this category of biomimetic materials. 
The present study data proved immediate and long-lasting desensitization with an 
average reduction of 3 to 4 VAS scores. In recently published in vitro evaluations the 
hydraulic conductance of dentin discs was significantly reduced after application of 
CPD-100 (experimental version of TMD)[26] and after application of the commercial 
product TMD [27]. These findings corroborate the present clinical data. An additional 
advantage of TMD is that the super saturation of saliva with calcium and phosphate 
might contribute to further HA crystal growth on an existing TMD layer in the long 
run [23,28]. 
 The positive control Gluma Desensitizer PowerGel (GLU) proved highly 
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effective with VAS score reductions of more than 4 scores relative to baseline. These 
results confirm findings of previous clinical studies, including a recent trial conducted 
at this research unit [17,29,30].Using confocal laser scanning microscopy, scanning 
and transmission electron microscopy Schüpbach et al. [31] visualized intrinsically 
blocked dentinal tubules to a depth of 200 µm inside the tubules following application 
of Gluma desensitizer. In a spectroscopic investigation the reaction mechanism 
between glutaraldehyde and 2-hydroxethylmethacrylate (HEMA) was described as a 
two-step reaction. First glutaraldehyde reacts with serum albumin inducing 
precipitation that mediates in a second step polymerization of HEMA [32]. 
 Generally, evaluation of treatment options for dentin hypersensitivity is a difficult 
task, since both placebo effects and natural desensitization over time may confound or 
overlap the clinical results due to apposition of peritubular and secondary dentin. 
Dentin hypersensitivity studies are pain studies. Therefore, it has to be taken into 
account that pain is associated with psychological and emotional effects that may 
affect patients’ pain response. The split-mouth study design selected for this trial 
seems to be the most appropriate model for this kind of studies, where the patients act 
as their own control [33]. 
 
 
CONCLUSIONS 
After the six-month follow-up of four treatment modalities for cervical dentin 
hypersensitivity it can be concluded that all desensitizing agents tested reduced 
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sensitivity significantly initially and over time. The highest reductions in sensitivity 
were obtained with the positive control GLU and the calcium-phosphate based 
product TMD. 
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Figure legends 
Fig. 1 Box-and-whisker plots of VAS scores after air blast stimulation by  desensitizing 
products and testing stages.  
             PRE = VAS before treatment.  
 POST = VAS immediately after treatment. 
Fig. 2 Box-and-whisker plots of VAS scores after probe scratching stimulation by 
 desensitizing products and testing stages. 
            PRE = VAS before treatment.  
 POST = VAS immediately after treatment. 
Fig. 3 Means of VAS sensitivity scores for air-blast stimulation (AB) by treatment  and 
testing times. The error bars denote the 95% intervals of confidence (CI).  PRE = VAS before 
treatment. POST = VAS immediately after treatment. Different lower-case letters next to the 
product abbreviations show that  desensitizer effects on sensitivity reduction were significantly 
different  according to Tukey’s post-hoc test. 
Fig. 4 Means of VAS sensitivity scores for probe-scratch stimulation (PS) by  treatment and 
testing times. The error bars denote the 95% intervals of  confidence (CI). PRE = VAS before 
treatment. POST = VAS immediately  after treatment. Different lower-case letters next to the 
product abbreviations  show that desensitizer effects on sensitivity reduction were significantly 
 different according to Tukey’s post-hoc test. 
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Table I Materials tested, composition, mechanism of action, application 
Material Manufacturer Batch/Exp. Composition Mechanism  Application 
Gluma 
Desensitizer 
PowerGel 
(GLU) 
HeraeusKulzer, 
Hanau, 
Germany 
031538/03-2015 Glutaraldehyde, 
hydroxyethyl-m
ethacrylate 
(HEMA), 
pyrogenic silica, 
water, dye 
Blocks tubules 
by 
precipitation 
of protein in 
dentin fluid 
Clean, rinse, 
application 60s 
dwell, rinse, 
air-dry 
MS Coat 
One F 
(MSC) 
Sun Medical 
Co., 
Shiga, Japan 
GG2/02-2016 Polymethyl-met
hacrylate, 
polystyrene 
sulphonic acid 
copolymer, 
oxalic acid, 
fluoride, water 
Reacts with 
tooth structure 
and forms 
precipitate that 
blocks dentin 
tubules 
Clean, dispense 
liquid and 
apply/rub with 
applicator for 30 
s, air-blast for 
5-10 s, rinse  
NanoSeal 
(NAN) 
Nippon 
ShikaYakuhin 
Co., Ltd. 
Shimonoseki, 
Japan 
A2E1/02-2015 A) F-Ca-Al-Si 
glass in aqueous 
dispersion 
 
B) H3PO4 
aqueous 
solution 
Reacts with 
tooth structure 
and forms 
precipitate that 
blocks dentin 
tubules 
Clean, rinse, 
mix A & B, 
apply to dentin 
for 20s, rinse 
with water 
Teethmate 
Desensitizer 
(TMD) 
Kuraray 
Noritake Dental 
Inc. Okayama, 
Japan 
011131/10-2015 Powder:Tetra-ca
lcium 
phosphate, 
Dicalcium 
phosphate 
anhydrous. 
Liquid: Water, 
preservative 
Powder-liquid 
mix reacts to 
form hydroxy- 
apatite. 
Sealing of 
dentin 
Clean, rinse, 
dispense and 
mix powder and 
liquid (15 s), 
apply with 
applicator, rub 
for 30 s, rinse 
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Table II Numbers of teeth treated by age groups and gender 
 
Age groups of patients (in years) 
<21 21-30 31-40 41-50 
Female 1 9 23 1 
Male -  3 11 2 
Total 1 12 34 3 
 
 
 
 
 
 
 
Table III Distribution of teeth by location and treatment (n = 50) 
 Maxillary Mandibular 
 MSC NAN TMD GLU MSC NAN TMD GLU 
Laterals 3 1 - - - - 1 2 
Canines 20 10 - - 1 2 3 8 
Premolars 24 33 2 2 1 2 36 34 
Molars 1 2 - - - - 8 4 
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Figure 1. Box-and-whisker plots of VAS scores after air blast stimulation by 
desensitizing products and testing stages.  
PRE = VAS before treatment.  
POST = VAS immediately after treatment. 
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Figure 2. Box-and-whisker plots of VAS scores after probe scratching stimulation by 
desensitizing products and testing stages. 
PRE = VAS before treatment.  
POST = VAS immediately after treatment. 
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Figure 3. Means of VAS sensitivity scores for air-blast stimulation (AB) by treatment 
and testing times. The error bars denote the 95% intervals of confidence (CI). 
PRE=VAS before treatment. POST=VAS immediately after treatment. Different 
lower-case letters next to the product abbreviations show that  desensitizer effects 
on sensitivity reduction were significantly different according to Tukey’s post-hoc 
test. 
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Figure 4. Means of VAS sensitivity scores for probe-scratch stimulation (PS) by 
treatment and testing times. The error bars denote the 95% intervals of confidence 
(CI). PRE=VAS before treatment. POST=VAS immediately after treatment. Different 
lower-case letters next to the product abbreviations show that desensitizer effects on 
sensitivity reduction were significantly different according to Tukey’s post-hoc test. 
 
 
 
 
